Pharmaceutical Executive
March 11, 2016
Features
36
3
Positioning for success in biopharma requires a self-critical analysis of the risk and rewards among four categories of value differentiation. The key question: How do you define yourself against the competition?
March 08, 2016
Columns
36
3
As new ICH GCP draft guidelines now require root cause analysis, novel methods for risk analysis and triage must be adopted in drug development.
March 07, 2016
From the Editor
36
3
With the emerging industry commitment to publicly disclose research and clinical trial results, two pivotal issues come to mind - and serve as a reminder to companies that true transparency depends on the truthfulness of the evidence that binds it.
March 07, 2016
Features
36
3
A new wave of technologies supported by innovative business models is transforming the vaccine landscape - and raising the bar on performance. As the demand for cures for chronic diseases accelerates, and with more global outbreaks of viral diseases like Zika and Ebola a virtual certainty, solutions can’t come soon enough.
March 06, 2016
Features
36
3
Can novel drug delivery technologies offering options beyond the traditional tablet or syringe transform the therapeutic experience for patients?
March 03, 2016
Columns
36
3
More generics and biosimilars may generate competition - but FDA opposes broad compounding.
March 01, 2016
Columns
36
3
Europe’s contrasting views on rare disease drugs - one bashing pricing abuses, the other extolling their public health virtues - could ultimately leave these products out in the cold.
March 01, 2016
Special Sponsored Section
36
3
The Dutch healthcare system, dubbed today as a “laboratory for change,” is in the midst of reinventing itself around collaborations with industry and government in such areas as market and patient access, transparency, cost-effectiveness, and process innovation.
March 01, 2016
Issue PDF
36
3
Click the title above to open the Pharmaceutical Executive March 2016 issue in an interactive PDF format.